PEPTIDE GUIDE

What Is Ovagen?

Ovagen is a commercially used name usually assigned to the experimental tripeptide glutamic acid-aspartic acid-leucine, abbreviated EDL. It is grouped with the Russian short-peptide bioregulators, but its identity and organ association are unusually confused across secondary sources.

The name can suggest an ovarian product, and some sellers make reproductive claims. The traceable scientific record for EDL instead concerns cultured rat kidney tissue and several rat models of kidney injury. PubMed searches for “Ovagen” also return studies of an unrelated veterinary follicle-stimulating hormone preparation used to induce ovulation in livestock.

No published human treatment trial of the EDL peptide was identified. There is no evidence that it improves fertility, ovarian reserve, menopause symptoms or human kidney disease.

Research statusPreclinical kidney research only; no published human treatment trial identified
Compound typeExperimental three-amino-acid peptide, identity inconsistently documented
Human evidenceNo published human treatment study identified
ApprovalNot approved by FDA, MHRA or EMA
Last reviewedOctober 2026
THE SHORT ANSWER

Ovagen is most commonly described as the EDL tripeptide, but the trade-name connection is not consistently documented in primary papers. Studies naming EDL report changes in cultured rat kidney cells and in rats with kidney injury caused by cisplatin, gentamicin or interrupted blood flow. These experiments do not establish an ovarian effect, fertility benefit or treatment for human kidney disease. Studies of the veterinary product also called Ovagen concern a hormone mixture, not EDL. Human identity-controlled trials, pharmacokinetics and safety data are absent.

What is Ovagen made from?

The sequence most often assigned to peptide Ovagen is:

`Glu-Asp-Leu (EDL)`

These names refer to glutamic acid, aspartic acid and leucine. A tripeptide contains three amino-acid residues linked by two peptide bonds. Glutamic acid and aspartic acid usually carry acidic side chains under biological conditions, while leucine has a hydrophobic side chain that tends to avoid water.

Primary kidney papers generally call the compound EDL or T-35 rather than Ovagen. The link between that exact sequence and the commercial name rests largely on tables, reviews and product descriptions associated with the wider bioregulator programme. This should be stated openly because a trade name is not chemical proof.

Why is the identity confusing?

At least three sources of confusion overlap. First, “Ovagen” sounds ovarian even when some descriptions place the peptide with liver, gastrointestinal or kidney research. Second, indexed EDL studies usually omit the trade name. Third, Ovagen is also a veterinary brand name used for an ovine follicle-stimulating hormone preparation.

Follicle-stimulating hormone, abbreviated FSH, is a much larger hormone released by the pituitary gland. In females it supports growth of ovarian follicles, the structures containing developing eggs. Veterinary Ovagen contains gonadotrophin material used in livestock reproduction and is not a three-amino-acid peptide.

Search results involving superovulation, oocyte production or sheep follicles therefore cannot be used as evidence for EDL. Any guide that merges these records creates a false fertility evidence base.

Is Ovagen an ovarian peptide?

The name alone does not establish an ovarian origin or action. No indexed paper was identified in which analytically confirmed EDL was tested in ovarian cells, an animal model of ovarian ageing or women receiving fertility treatment.

Ovarian function depends on a coordinated hormonal system involving the hypothalamus, pituitary gland and ovaries. Follicle-stimulating hormone and luteinising hormone control follicle growth and ovulation, while ovarian hormones feed information back to the brain. A small peptide would need evidence showing where it acts within this system.

There are no published EDL data for anti-Müllerian hormone, antral follicle count, ovulation, egg quality, pregnancy, live birth or menopause symptoms. Calling the compound an ovarian bioregulator therefore goes beyond the traceable evidence.

What did the kidney-tissue culture study examine?

A 2015 paper tested a polypeptide complex isolated from calf kidneys alongside two short peptides, AED and EDL, in organotypic kidney cultures from young and old rats. An organotypic culture keeps small tissue fragments alive outside the body while preserving some local cell relationships.

The researchers measured Ki-67, a protein associated with cells progressing through the division cycle, and p53, a protein involved in responses to DNA damage, cell-cycle control and programmed cell death. They reported that EDL increased proliferation and reduced apoptosis in kidney cells, although its effects were smaller than those of the tissue-derived polypeptide complex.

An altered marker does not prove kidney regeneration. Ki-67 does not show that new cells have become fully functioning filtration structures, and lower p53 is not automatically beneficial. The experiment could not measure urine production, blood filtration, circulation or whole-body toxicity because the tissue was outside the rat.

What did the earlier kidney-cell ageing study find?

Researchers also examined a calf-kidney polypeptide complex, AED and EDL in primary rat kidney-cell cultures aged in the laboratory. Primary cells are taken directly from tissue and usually resemble their source more closely than immortalised cell lines, although culture conditions still change their behaviour.

The study measured Ki-67 and p53, matrix metalloproteinase-14 and interleukin-8. Matrix metalloproteinase-14, abbreviated MMP-14, helps remodel the extracellular matrix, the network of material surrounding cells. Interleukin-8 is an inflammatory signalling protein.

The authors reported that MMP-14 was a target of EDL under their conditions, while the tissue complex and AED had clearer effects on cell-renewal markers. This is a molecular association in cultured cells. It does not show that EDL prevents scarring or improves filtration in a living kidney.

What do studies of “cellular ageing” show?

A related paper reported that AED and EDL increased proliferation, reduced expression of p16, p21 and p53, and increased SIRT6 in young and aged renal cell cultures. P16 and p21 help restrain cell division. SIRT6 is an enzyme involved in DNA repair, metabolism and chromatin regulation.

These proteins are often discussed as ageing markers, but changing them does not reverse the age of an organism. Cellular senescence is a state in which a stressed or damaged cell stops dividing and changes its signalling. It can contribute to age-related dysfunction, but it also suppresses the growth of damaged cells.

Reducing a senescence-associated marker could represent altered cell state, increased proliferation or selective survival. Researchers would need to show preserved genetic stability and kidney function before describing the effect as rejuvenation.

What happened in the cisplatin kidney-injury study?

Cisplatin is a chemotherapy medicine that can damage the kidneys. A rat study examined a kidney polypeptide complex and the short peptides AED, EDL and AEDG in cisplatin-induced acute renal failure.

The paper reported that EDL and AEDG normalised several measurements, including urine output, urinary creatinine, estimated glomerular filtration, sodium reabsorption and urinary protein and electrolyte concentrations. The authors described EDL as having a marked nephroprotective effect. Nephroprotective means protecting kidney structure or function from injury.

This was an animal model of a specific toxic injury. Rat kidneys, exposure conditions and timing differ from treatment of a person receiving chemotherapy. The abstract does not provide enough detail to judge masking, allocation concealment or all exclusions. Most importantly, preventing injury in rats does not demonstrate safety alongside human cancer treatment, where interactions and any effect on chemotherapy activity would need careful testing.

What happened in the gentamicin and ischaemia study?

A 2017 paper tested EDL in two rat models. One used gentamicin, an antibiotic capable of causing kidney toxicity. The other used ischaemia followed by reperfusion, meaning that kidney blood flow was interrupted and then restored. Reperfusion can itself trigger oxidative and inflammatory damage.

The authors reported prevention of very low urine output and retention of nitrogen-containing waste in the blood. They also reported lower urinary protein and sodium loss, preservation of antioxidant-enzyme activity, reduced lipid peroxidation and improved measurements related to cellular energy.

Lipid peroxidation is oxidative damage to fats in cell membranes. Antioxidant enzymes help control chemically reactive molecules. These biomarkers can support an interpretation, but the clinically important question is whether treatment preserves kidney function without other harm.

The experiment supplies preclinical evidence in rats. It does not establish benefit for human acute kidney injury, which can arise from infection, low blood pressure, obstruction, immune disease, medicines and many other causes.

Were old rats also studied?

A later study examined a kidney polypeptide complex, AED, EDL and AEDG in old rats. The indexed abstract reports effects on kidney function across the peptide groups, but its summary highlights particular numerical findings for AEDG rather than providing a complete EDL result set.

This makes it unsafe to attribute every reported improvement to Ovagen or EDL. Multi-intervention papers require compound-by-compound reading. Group findings cannot be pooled simply because all tested substances belong to the same programme.

Ageing rats can model selected changes in filtration and tissue structure, but human chronic kidney disease develops through diverse causes, including diabetes, high blood pressure, immune disease and inherited conditions. An old-animal experiment cannot substitute for diagnosis-specific clinical research.

Does normalising creatinine prove kidney recovery?

No single measurement is enough. Creatinine is a waste product generated largely from muscle metabolism and cleared mainly through the kidneys. Blood creatinine is used to estimate glomerular filtration rate, the volume of fluid filtered by the kidney's microscopic filtering units over time.

Urinary creatinine and calculated filtration can shift with hydration, muscle mass, urine collection and the experimental method. Protein in urine can indicate damage to the filtration barrier, but it also varies by cause and timing. A consistent pattern across function, tissue examination and survival is more persuasive than one biomarker.

The rat EDL papers report several aligned measurements, which is more informative than a single marker. They remain animal findings and need independent replication with transparent methods before clinical translation.

Does EDL act through antioxidant pathways?

The gentamicin and ischaemia paper reports preservation of antioxidant enzymes and suppression of lipid peroxidation. This suggests that oxidative damage accompanied the measured kidney effects.

It does not prove that EDL directly neutralises reactive molecules. The peptide could alter metabolism, inflammation, blood flow or cell survival, with antioxidant measurements changing secondarily. The paper does not identify a unique receptor or enzyme target that explains all findings.

“Antioxidant” is also not equivalent to clinically useful. Reactive molecules participate in normal signalling and defence as well as damage. A treatment needs evidence that it improves a disease outcome at a safe exposure, not merely that an oxidation marker changes.

Does EDL bind DNA?

A 2016 paper used computational modelling to propose binding between multiple short peptides and selected DNA sequences. It reported a model in which EDL and AEDL associated with a CTCC sequence.

Computational docking predicts arrangements that appear physically plausible according to a model. It does not show that intact EDL enters a living human kidney cell, reaches the nucleus, binds that sequence among billions of DNA bases or changes a clinically relevant gene.

Direct binding assays, cellular target-engagement experiments and functional tests are needed. The published kidney effects could also arise through indirect signalling. The molecular mechanism therefore remains unresolved.

Is EDL specific to the kidneys?

That has not been demonstrated. The EDL papers focus on kidney tissue, but experimental focus is not the same as selective distribution. A peptide may be studied in one organ because researchers chose that model.

To establish specificity, investigators would need to administer analytically verified EDL and measure intact peptide across blood, kidney, liver, brain and other tissues over time. They would also need to compare molecular responses in different organs. No human biodistribution study exists.

The inconsistent description of Ovagen as ovarian, hepatic, gastrointestinal or renal makes objective distribution work especially necessary. Marketing categories cannot resolve a chemical and biological question.

Has peptide Ovagen been tested in humans?

No published human treatment trial or registered clinical study of analytically confirmed EDL under the Ovagen name was identified through October 2026. There is no Phase I programme defining safety, tolerability or pharmacokinetics.

Pharmacokinetics describes how a substance is absorbed, distributed, broken down and cleared. For a kidney-associated compound, renal clearance can complicate interpretation because kidney injury itself may change exposure.

There is no controlled human evidence for acute kidney injury, chronic kidney disease, proteinuria, fertility, menopause, ovarian reserve or healthy ageing. Veterinary FSH studies do not fill any of these gaps.

What would credible human kidney evidence require?

Early development would begin with verified EDL, validated analytical assays and toxicity studies. Researchers would need to establish whether intact peptide reaches circulation and kidney tissue and whether impaired kidney function causes accumulation.

Clinical trials would enrol people with a clearly defined condition. Acute kidney injury after surgery differs from antibiotic toxicity or chronic diabetic kidney disease. Random allocation would create comparable groups, while masking would reduce differences in care and assessment caused by expectations.

Outcomes could include blood creatinine, measured or estimated filtration, urine protein, need for dialysis, hospital stay, recovery and survival. Biomarkers of oxidative stress could support the analysis but would not replace patient outcomes. Follow-up would need to detect delayed loss of function and effects outside the kidney.

No such programme has been published for EDL.

What would credible fertility evidence require?

First, researchers would need a biological reason to expect EDL to influence ovarian function and evidence that it reaches ovarian tissue. Studies should examine hormone signalling, follicles and egg cells without assuming an effect from the trade name.

Human fertility trials would define the population, such as diminished ovarian reserve or people undergoing in vitro fertilisation. Relevant outcomes could include mature eggs retrieved, fertilisation, embryo development, pregnancy and live birth. Hormone measurements alone would not prove improved fertility.

Safety would include ovarian over-response, pregnancy outcomes and effects on the developing child. None of this evidence exists for peptide Ovagen.

What is known about safety?

There is no adequate human safety profile. Rat injury studies were designed mainly to examine kidney effects and cannot rule out reactions in other organs, interactions with medicines, reproductive effects or delayed harm.

Changing proliferation, apoptosis or matrix-remodelling proteins can have different consequences in healthy and damaged tissue. Lower p53 activity, for example, cannot be labelled beneficial without evidence that damaged cells remain controlled. Long-term carcinogenicity and reproductive toxicology have not been established.

Product identity is an immediate safety concern. A vial labelled Ovagen could be confused conceptually with veterinary FSH or could contain material whose sequence and amount have not been independently confirmed. Sterility and bacterial endotoxins require separate testing. Endotoxins are inflammatory bacterial components that can remain without living bacteria.

Kidney disease can alter fluid, electrolyte and medicine handling and may become life-threatening. An experimental peptide should not delay medical assessment or established treatment.

How is EDL synthesised and checked?

EDL can be assembled through solid-phase peptide synthesis. Protected amino acids are coupled in order while the chain remains attached to a resin. Temporary protecting groups limit unintended reactions. The completed peptide is then released, deprotected and purified.

Mass spectrometry can test molecular mass, and fragmentation can add sequence information. Chromatography separates EDL from shortened chains and related impurities. Analysis may also assess peptide content, water, counterions, residual solvents and degradation.

For regulated sterile research, each batch would require identity, potency, particle, sterility, endotoxin and stability controls. A certificate using the Ovagen name without sequence-specific testing would not resolve the identity problem. This overview is not a manufacturing recipe.

How did the Ovagen and EDL record develop?

PeriodDevelopment
Earlier decadesOvagen became a veterinary brand for an ovine FSH preparation used in livestock
2000s onwardEDL appeared within Russian short-peptide and kidney research under sequence or T-35 labels
2014 to 2015Kidney-cell and organotypic-culture papers reported marker changes
2015 to 2017Rat cisplatin, gentamicin and ischaemia studies reported kidney-function effects
Late 2010s onwardCommercial sources increasingly attached the Ovagen name to EDL with inconsistent organ claims
Through October 2026No published human treatment trial of peptide Ovagen was identified

Is Ovagen approved?

The EDL peptide sold as Ovagen is not approved by the United States Food and Drug Administration, the United Kingdom Medicines and Healthcare products Regulatory Agency or the European Medicines Agency.

This statement concerns peptide EDL. Veterinary reproductive products with the same name have their own formulations and regulatory status and should not be confused with it.

How strong is the evidence overall?

QuestionBest available evidenceDefensible conclusion
Is peptide Ovagen definitively EDL?Secondary naming sources; primary papers use EDL or T-35Commonly assigned, but documentation is incomplete
Does EDL affect cultured rat kidney tissue?Several cell and explant studiesSelected proliferation and matrix markers changed
Does EDL affect rat kidney injury?Cisplatin, gentamicin and ischaemia modelsFunctional and biochemical changes were reported
Does it improve ovarian function or fertility?No relevant EDL study identifiedNot established
Does it treat human kidney disease?No human treatment studyUnknown
Is it safe in people?No adequate human exposure studyUnknown
Is it approved as a human medicine?No FDA, MHRA or EMA approvalNo
FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What is Ovagen?

It is a trade name most commonly attached to the experimental EDL tripeptide.

What is its sequence?

It is usually reported as Glu-Asp-Leu, abbreviated EDL, although the name-to-sequence documentation is limited.

Is Ovagen an ovarian peptide?

No traceable EDL study establishes ovarian targeting or benefit.

Is peptide Ovagen the veterinary fertility product?

No. Veterinary Ovagen is a follicle-stimulating hormone preparation and is unrelated to the EDL tripeptide.

Does Ovagen improve fertility?

No human or animal EDL evidence demonstrates improved fertility.

Does EDL protect the kidneys?

Kidney-function effects were reported in rat injury models, but human benefit has not been tested.

Does Ovagen reverse kidney ageing?

Cell-marker changes in rat cultures do not establish reversal of kidney ageing.

Has it been tested in people?

No published human treatment study of peptide Ovagen was identified.

Is Ovagen known to be safe?

No adequate human safety profile exists.

Is peptide Ovagen approved?

It is not approved by the FDA, MHRA or EMA.

Research reviewed through October 2026.